ArticleScientific reports2025
Comprehensive analysis of lipid metabolic signatures identified CEBPD promotes breast cancer cell proliferation.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- scRNA-Seq reveals anti-lymphoma immune responses in mogamulizumab-associated skin eruptions.Journal of the European Academy of Dermatology and Venereology : JEADV · 2026Article
- Glucocorticoid-Induced Proteome and Phosphoproteome Changes in Breast Cancer Cell Lines.Journal of proteome research · 2026Article
- GNAL-driven calcium signaling reshapes the spatiotemporal immune landscape in ERTranslational cancer research · 2026Article
- Prognostic impact of the lipid metabolism gene AGPAT4 in the tumor immune microenvironment of thyroid cancer.Genomics & informatics · 2026Article
- Transcriptomic landscape of generalized pustular psoriasis before and after acitretin/glucocorticoids treatment.Clinical and experimental medicine · 2025Article
- Article
- Comprehensive analysis of the papillary thyroid carcinoma identifies CSGALNACT1 as a proliferation driver and prognostic biomarker.Frontiers in cell and developmental biology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Breast cancer (BRCA) remains the leading cause of cancer-related mortality worldwide, with lipid metabolism emerging as a critical factor in tumor progression that influences cell proliferation, migration, and immune response. Insights into lipid metabolism signatures and associated genes may offer new prognostic and therapeutic avenues. In this study, we leveraged scRNA-seq and bulk transcriptome data to assess the expression patterns and prognostic significance of lipid metabolism-related genes in BRCA. Through single-cell transcriptomic analysis of primary BRCA samples, we identified a specific set of lipid metabolism signature genes and constructed a prognostic risk model based on these signatures. This model enables patient stratification by risk scores, supporting an integrated analysis of lipid metabolism, immune landscape, and clinical outcomes. Importantly, we identified CEBPD, ABCA1, and CYP27A1 as independent prognostic genes linked to lipid metabolism, with functional assays revealing an inhibitory role for CEBPD in BRCA cell proliferation. Our findings underscore the influence of adipocytes in BRCA progression and propose CEBPD as a potential target for therapeutic intervention. This study provides a foundation for further exploration of metabolism-based strategies to enhance BRCA outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.